Rxivist logo

Moxifloxacin efficacy against Mycobacterium abscessus in vivo using zebrafish model

By Wenjuan Nie, Gao Shan, Tianlu Teng, Wenqiang Zhou, Yuanyuan Shang, Wei Jing, Wenhui Shi, Qingfeng Wang, Xuerui Huang, Baoyun Cai, Jun Wang, Jing Wang, Ru Guo, Qiping Ge, Lihui Nie, Xiqin Han, Yadong Du, Naihui Chu

Posted 05 Dec 2019
bioRxiv DOI: 10.1101/865824

Moxifloxacin (MFX) showed good activity in vitro against Mycobacterium abscessus (M. abscessus) and was suggested as one of the antibiotic regimens for adults with M. abscessus disease. However, some other studies showed that MFX showed less or none activity against M. abscessus. In our study we aim to evaluate MFX activity against M. abscessus using zebrafish (ZF) model in vivo. MIC of each drugs were determined by broth microdilution method. M. abscessus labeled by CM-DiI, were micro-injected into ZF. Survival curves were determined by recording dead ZF every day. After 4 days of incubation ZF were lysed. Colony-forming unit (CFU) were enumerated and results are expressed as mean log10 CFU per ZF. Bacteria dissemination and fluorescence intensity in ZF were observed and analyzed. Inhibition rate was also calculated. In our study MFX showed good activity in vitro. But in vivo MFX showed limited restriction to M. abscessus. The association between increased survival and high dose of MFX is not significant. Same results were observed in bacterial fluorescence intensity and inhibition rates, with no significant difference when compared with no drug group (P>0.05). However, significant difference was observed in azithromycin (AZM) group. MFX showed limited efficacy on Mycobacterium abscessus in vivo using ZF model. MFX's activity in vivo needs to be confirmed.

Download data

  • Downloaded 265 times
  • Download rankings, all-time:
    • Site-wide: 164,413
    • In microbiology: 11,891
  • Year to date:
    • Site-wide: 157,120
  • Since beginning of last month:
    • Site-wide: 101,910

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide